glp-1 drug updates Medicare is about to cover drugs for weight loss. Here's what to know While many patients are seeing

Emerging preclinical evidence suggests GLP-1 may influence neuronal survival, synaptic plasticity, and neuroinflammationprocesses that are disrupted in neurodegenerative conditions

Some companies are looking beyond GLP-1 and other hot targets like GIP and glucagon to emerging areas like amylin, another hormone produced in the pancreas that helps people feel full

The study was a secondary data analysis and did not include patients as study participants

Available online at: (accessed May, 2026) 35 WangW.VolkowN

How will these drugs be integrated into our healthcare system, and what factors will facilitate widespread adoption